Amivantamab plus chemotherapy with or without lazertinib in EGFR- mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
home / between-the-lines / amivantamab-plus-chemotherapy-with-or-without-lazertinib-in-egfr-mutant-advanced-nsclc
Expert perspectives on the phase III MARIPOSA-2 trial results evaluating amivantamab-based regimens in EGFR-mutant NSCLC after osimertinib progression. The discussion covers efficacy, safety, clinical implications, and future directions featuring Dr. Martin Dietrich.
